Inogen, Inc. (NASDAQ:INGN) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its position in Inogen, Inc. (NASDAQ:INGN) by 30.0% during the 4th quarter, Holdings Channel reports. The firm owned 627,030 shares of the medical technology company’s stock after selling 269,076 shares during the quarter. JPMorgan Chase & Co.’s holdings in Inogen were worth $5,750,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Royce & Associates LP grew its stake in Inogen by 499.7% in the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock valued at $2,854,000 after acquiring an additional 259,308 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Inogen by 141.5% in the fourth quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company’s stock valued at $3,301,000 after purchasing an additional 210,961 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Inogen by 42.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company’s stock valued at $2,282,000 after purchasing an additional 74,197 shares during the last quarter. Monaco Asset Management SAM increased its stake in shares of Inogen by 104.0% during the 4th quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company’s stock worth $702,000 after purchasing an additional 39,000 shares in the last quarter. Finally, Stokes Family Office LLC raised its position in shares of Inogen by 29.0% during the 4th quarter. Stokes Family Office LLC now owns 163,500 shares of the medical technology company’s stock worth $1,499,000 after purchasing an additional 36,715 shares during the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Stock Performance

Shares of INGN opened at $6.82 on Friday. The company’s 50 day simple moving average is $8.02 and its 200 day simple moving average is $9.16. Inogen, Inc. has a 1 year low of $6.40 and a 1 year high of $13.33. The company has a market capitalization of $183.37 million, a price-to-earnings ratio of -3.03 and a beta of 1.48.

Wall Street Analyst Weigh In

A number of brokerages have commented on INGN. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, April 9th. StockNews.com cut Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.